EHI
MRTX

Eagle Health Investments’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Eagle Health Investments’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-52,000
Closed -$4.28M – 32
2022
Q1 		$4.28M Hold
52,000
– – 1.05% 21
2021
Q4 		$7.63M Hold
52,000
– – 1.86% 20
2021
Q3 		$9.2M Sell
52,000
-5,900
-10% -$949K 2.92% 16
2021
Q2 		$9.35M Buy
57,900
+21,500
+59% +$3.45M 3.21% 15
2021
Q1 		$6.24M Buy
+36,400
New +$7.21M 2.45% 17

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Eagle Health Investments's MRTX Position: Q2 2022 in Review

Eagle Health Investments sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2022, closing a stake of 52,000 shares — an estimated $4.28M sold.

Eagle Health Investments first reported a position in MRTX in Q1 2021 and held it in 5 quarters. The position peaked at $9.35M in Q2 2021. 230 funds tracked by Wall St. Rank hold MRTX as of Q2 2022.

  • Eagle Health Investments reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Eagle Health Investments sold 52,000 Mirati Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $4.28M.
  • Eagle Health Investments first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
  • Eagle Health Investments's Mirati Therapeutics, Inc. Common Stock position peaked at $9.35M in Q2 2021.
  • 230 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Eagle Health Investments's 13F filing for Q2 2022, filed 11 Aug 2022.